Castle Biosciences Inc. (NASDAQ:CSTL) shares traded higher over the last trading session, gaining 4.50% on 02/11/21. The shares fell to a low of $89.99 before closing at $94.20. Intraday shares traded counted 0.14 million, which was 56.71% higher than its 30-day average trading volume of 327.83K. CSTL’s previous close was $90.14 while the outstanding shares total 19.94M. The firm The stock’s Relative Strength Index (RSI) is 65.00, with weekly volatility at 9.29% and ATR at 6.68. The CSTL stock’s 52-week price range has touched low of $21.01 and a $107.69 high.
Investors have identified the Diagnostics & Research company Castle Biosciences Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $2.14 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Castle Biosciences Inc. (CSTL) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For CSTL, the company has in raw cash 183.05 million on their books with 10.0 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 201.06 million total, with 30.24 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -0.12 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on CSTL sounds very interesting.
Is the stock of CSTL attractive?
In related news, Director, BRADBURY DANIEL sold 6,500 shares of the company’s stock in a transaction that recorded on Feb 10. The sale was performed at an average price of 93.31, for a total value of 606,547. As the sale deal closes, the Pres. & Chief Exec. Officer, MAETZOLD DEREK J now sold 14,375 shares of the company’s stock, valued at 1,358,039. Also, Pres. & Chief Exec. Officer, MAETZOLD DEREK J sold 14,375 shares of the company’s stock in a deal that was recorded on Feb 09. The shares were price at an average price of 96.29 per share, with a total market value of 1,384,112. Following this completion of acquisition, the Director, BRADBURY DANIEL now holds 8,500 shares of the company’s stock, valued at 823,706. In the last 6 months, insiders have changed their ownership in shares of company stock by 4.10%.
4 out of 5 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on Castle Biosciences Inc.. 0 analysts has assigned a Sell rating on the CSTL stock. The 12-month mean consensus price target for the company’s shares has been set at $84.20.